Human abuse liability assessment of oxycodone combined with ultra-low-dose naltrexone

Psychopharmacology

Volumn 210, Issue 4, 2010, Pages 471-480

  Tompkins, David Andrew ^a,b   Lanier, Ryan K ^a,c   Harrison, Joseph A ^a   Strain, Eric C ^a   Bigelow, George E ^a  

^a JOHNS HOPKINS UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b JOHNS HOPKINS UNIVERSITY   (United States)

^c Rock Creek Pharmaceuticals Inc   (United States)

Author keywords

Abuse liability; OPIOID; Oxytrex; PTI 801; Ultra low dose naltrexone

Indexed keywords

BENZODIAZEPINE; COCAINE; NALTREXONE; OXYCODONE; PLACEBO;

ADULT; ANALGESIC ACTIVITY; ARTICLE; BREATHING RATE; CLINICAL ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; COST EFFECTIVENESS ANALYSIS; CROSSOVER PROCEDURE; DOSE RESPONSE; DOUBLE BLIND PROCEDURE; DRUG ANTAGONISM; DRUG COST; DRUG POTENCY; DRUG POTENTIATION; FEMALE; HEART RATE; HUMAN; LOW DRUG DOSE; MALE; MYDRIASIS; OPIATE ADDICTION; OXYGEN SATURATION; PRIORITY JOURNAL; RESPONSE TIME; TREND STUDY; UNSPECIFIED SIDE EFFECT;

ADOLESCENT; ADULT; AGED; ANALGESICS, OPIOID; BEHAVIOR, ADDICTIVE; DOSE-RESPONSE RELATIONSHIP, DRUG; DOUBLE-BLIND METHOD; DRUG THERAPY, COMBINATION; FEMALE; HUMANS; MALE; MIDDLE AGED; NALTREXONE; OPIOID-RELATED DISORDERS; OXYCODONE; PLACEBOS;

EID: 77955655108     PISSN: 00333158     EISSN: 14322072     Source Type: Journal    
DOI: 10.1007/s00213-010-1838-3     Document Type: Article

References (43)

1. Alho H, Sinclair D, Vuori E, Holopainen A (2007) Abuse liability of buprenorphine-naloxone tablets in untreated IV drug users. Drug Alcohol Depend 88:75-78
2. Borsook D, Becerra L, Carlezon WA Jr, Shaw M, Renshaw P, Elman I, Levine J (2007) Reward-aversion circuitry in analgesia and pain: implications for psychiatric disorders. Eur J Pain 11:7-20
3. Buchsbaum MS, Davis GC, Bunney WE Jr (1977) Naloxone alters pain perception and somatosensory evoked potentials in normal subjects. Nature 270:620-622
4. Chakrabarti S, Regec A, Gintzler AR (2005) Biochemical demonstration of mu-opioid receptor association with Gsa: enhancement following morphine exposure. Brain Res Mol Brain Res 135:217-224
5. Chindalore VL, Craven RA, Yu KP, Butera PG, Burns LH, Friedmann N (2005) Adding ultra-low-dose naltrexone to oxycodone enhances and prolongs analgesia: a randomized, controlled trial of Oxytrex. J Pain 6:392-399
6. Cicero TJ, Adams EH, Geller A, Inciardi JA, Munoz A, Schnoll SH, Senay EC, Woody GE (1999) A postmarketing surveillance program to monitor Ultram (tramadol hydrochloride) abuse in the United States. Drug Alcohol Depend 57:7-22
7. Cicero TJ, Inciardi JA, Munoz A (2005) Trends in abuse of Oxycontin and other opioid analgesics in the United States: 2002-2004. J Pain 6:662-672
8. Comer SD, Sullivan MA, Whittington RA, Vosburg SK, Kowalczyk WJ (2008) Abuse liability of prescription opioids compared to heroin in morphine-maintained heroin abusers. Neuropsychopharmacology 33:1179-1191
9. Crain SM, Shen KF (1995) Ultra-low concentrations of naloxone selectively antagonize excitatory effects of morphine on sensory neurons, thereby increasing its antinociceptive potency and attenuating tolerance/dependence during chronic cotreatment. Proc Natl Acad Sci 92:10540-10544
10. Crain SM, Shen KF (2000) Antagonists of excitatory opioid receptor functions enhance morphine's analgesic potency and attenuate opioid tolerance/dependence liability. Pain 84:121-131
11. Flugsrud-Breckenridge MR, Gevirtz C, Paul D, Gould HJ 3rd (2007) Medications of abuse in pain management. Curr Opin Anaesthesiol 20:319-324
12. Gan TJ, Ginsberg B, Glass PS, Fortney J, Jhaveri R, Perno R (1997) Opioid-sparing effects of a low-dose infusion of naloxone in patient-administered morphine sulfate. Anesthesiology 87:1075-81
13. Griffiths RR, Troisi JR, Silverman K, Mumford GK (1993) Multiplechoice procedure: an efficient approach for investigating drug reinforcement in humans. Behav Pharmacol 4:3-13 (Pubitemid 23062644)
14. Griffiths RR, Bigelow GE, Ator NA (2003) Principles of initial experimental drug abuse liability assessment in humans. Drug Alcohol Depend 70: S41-54
15. Gueneron JP, Ecoffey C, Carli P, Benhamou D, Gross JB (1988) Effect of naloxone infusion on analgesia and respiratory depression after epidural fentanyl. Anesth Analg 67:35-38
16. Handelsman L, Cochrane KJ, Aronson MJ, Ness R, Rubinstein KJ, Kanof PD (1987) Two new rating scales for opiate withdrawal. Am J Drug Alcohol Abuse 13:293-308
17. Largent-Milnes TM, Guo W, Wang H, Burns LH, Vanderah TW (2008) Oxycodone plus ultra-low-dose naltrexone attenuates neuropathic pain and associated mu-opioid receptor-Gs coupling. J Pain 9:700-713
18. Leri F, Burns LH (2005) Ultra-low-dose naltrexone reduces the rewarding potency of oxycodone and relapse vulnerability in rats. Pharmacol Biochem Behav 82:252-262
19. Levine JD, Gordon NC, Fields HL (1979) Naloxone dose dependently produces analgesia and hyperalgesia in postoperative pain. Nature 278:740-741
20. McCabe SE, Boyd CJ, Young A (2007a) Medical and nonmedical use of prescription drugs among secondary school students. J Adolesc Health 40:76-83
21. McCabe SE, Morales M, Cranford JA, Delva J, McPherson MD, Boyd CJ (2007b) Race/ethnicity and gender differences in drug use and abuse among college students. J Ethn Subst Abuse 6:75-95
22. Morley-Forster PK, Clark AJ, Speechley M, Moulin DE (2003) Attitudes toward opioid use for chronic pain: a Canadian physician survey. Pain Res Manag 8:189-194
23. Nestler EJ (2004) Molecular mechanisms of drug addiction. Neuropharmacology 47 (Suppl 1):24-32
24. Novak S, Nemeth WC, Lawson KA (2004) Trends in medical use and abuse of sustained-release opioid analgesics: a revisit. Pain Med 5:59-65
25. Olmstead MC, Burns LH (2005) Ultra-low-dose naltrexone suppresses rewarding effects of opiates and aversive effects of opiate withdrawal in rats. Psychopharmacology (Berl) 181:576-581
26. Powell KJ, Abul-Husn NS, Jhamandas A, Olmstead MC, Beninger RJ, Jhamandas K (2002) Paradoxical effects of the opioid antagonist naltrexone on morphine analgesia, tolerance, and reward in rats. J Pharmacol Exp Ther 300:588-596
27. Rawal N, Schott U, Dahlstrom B, Inturrisi CE, Tandon B, Sjostrand U, Wennhager M (1986) Influence of naloxone infusion on analgesia and respiratory depression following epidural morphine. Anesthesiology 64:194-201
28. SAMHSA, Office of Applied Studies (2004) Drug Abuse Warning Network, 2003: Interim National Estimates of Drug-Related Emergency Department Visits. DAWN Series D-26, DHHS Publication No. (SMA) 04-3972
29. SAMHSA, Office of Applied Studies (2007) Treatment Episode Data Set (TEDS) Highlights - 2007 National Admissions to Substance Abuse Treatment Services. OAS Series S-45, DHHS Publication No. (SMA) 09-4360
30. Spiller H, Lorenz DJ, Bailey EJ, Dart RC (2009) Epidemiological trends in abuse and misuse of prescription opioids. J Addict Dis 28:130-136
31. Sproule B, Brands B, Li S, Catz-Biro L (2009) Changing patterns in opioid addiction: characterizing users of oxycodone and other opioids. Can Fam Physician 55:68-69
32. Stoller KB, Bigelow GE, Walsh SL, Strain EC (2001) Effects of buprenorphine/naloxone in opioid-dependent humans. Psychopharmacology (Berl) 154:230-242
33. Strain EC, Walsh SL, Preston KL, Liebson IA, Bigelow GE (1997) The effects of buprenorphine on buprenorphine-maintained volunteers. Psychopharmacology 129:329-338
34. Strain EC, Stoller K, Walsh SL, Bigelow GE (2000) Effects of buprenorphine versus buprenorphine/naloxone tablets in nondependent opioid abusers. Psychopharmacology 148:374-383
35. Tetrault JM, Desai RA, Becker WC, Fiellin DA, Concato J, Sullivan LE (2008) Gender and non-medical use of prescription opioids: results from a national US survey. Addiction 103:258-268
36. Walsh SL, Nuzzo PA, Lofwall MR, Holtman JR Jr (2008) The relative abuse liability of oral oxycodone, hydrocodone and hydromorphone assessed in prescription opioid abusers. Drug Alcohol Depend 98:191-202
37. Wang HY, Burns LH (2009) Naloxone's pentapeptide binding site on filamin A blocks Mu opioid receptor-Gs coupling and CREB activation of acute morphine. PLoS ONE 4: E4282
38. Wang HY, Friedman E, Olmstead MC, Burns LH (2005) Ultra-lowdose naloxone suppresses opioid tolerance, dependence and associated changes in mu opioid receptor-G protein coupling and Gß signaling. Neuroscience 135:247-261
39. Wang HY, Frankfurt M, Burns LH (2008) High-affinity naloxone binding to filamin a prevents mu opioid receptor-Gs coupling underlying opioid tolerance and dependence. PLoS ONE 3: E1554
40. Webster LR (2007) Oxytrex: an oxycodone and ultra-low-dose naltrexone formulation. Expert Opin Investig Drugs 16:1277-1283
41. Webster LR, Butera PG, Moran LV, Wu N, Burns LH, Friedmann N (2006) Oxytrex minimizes physical dependence while providing effective analgesia: a randomized controlled trial in low back pain. J Pain 7:937-946
42. Wise RA (1989) Opiate reward: sites and substrates. Neurosci Biobehav Rev 13:129-133
43. Zacny JP, Gutierrez S (2003) Characterizing the subjective, psychomotor, and physiological effects of oral oxycodone in non-drugabusing volunteers. Psychopharmacology 170:242-54